HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression.
Leuk Res
; 31(7): 921-9, 2007 Jul.
Article
em En
| MEDLINE
| ID: mdl-17056111
ABSTRACT
FLT3 mutations and cell-surface antigen were investigated in 29 DR-negative (DR(-)) M1/M2 AML samples in comparison with 30 DR-positive (DR(+)) M1/M2 AML samples. FLT3-ITD was detected in 59.3% and D835 was detected in 7.4% of the samples. The incidence of FLT3-ITD was higher in the DR(-) group (59.3%) than in the DR(+) group (17.9%; P=0.002). The DR(-) status was associated with the CD34(-) (82.8%), CD7(-) (92.9%) and CD45RO(+) status (76%). Our results indicated that FLT3 mutation is the most common gene alteration found in the DR(-) M1/M2 AML. These results are important for further characterizing this phenotypic AML entity.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
/
Antígenos HLA-DR
/
Tirosina Quinase 3 Semelhante a fms
/
Mutação
/
Antígenos de Superfície
Limite:
Humans
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article